Clarithromycin as Immunomodulator for the Management of Sepsis

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

April 30, 2011

Conditions
SepsisSevere SepsisSeptic Shock
Interventions
DRUG

Clarithromycin

1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days

DRUG

Dextrose 5%

1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days

Trial Locations (6)

11528

3rd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Athens

12462

2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Athens

4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens

15126

2nd Department of Medicine, Sismanogleion General Hospital, Athens

24100

1st Department of Medicine, University of Patras, Pátrai

54635

2nd Department of Surgery, University of Thessaloniki, Thessaloniki

All Listed Sponsors
lead

University of Athens

OTHER

NCT01223690 - Clarithromycin as Immunomodulator for the Management of Sepsis | Biotech Hunter | Biotech Hunter